BridgeMD
New treatment option for Lichen Plano-Pilaris
Official title Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.
ClinicalTrials.gov ID: NCT07396168
What this study is testing
What is Nemolizumab?
Nemolizumab is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for lichen plano-pilaris.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia characterized by progressive, permanent hair loss and scalp symptoms such as pruritus and burning. Current treatments-including topical and intralesional corticosteroids, hydroxychloroquine, and immunosuppressants-are often inadequate, with limited evidence for efficacy and frequent treatment switching or discontinuation due to side effects or lack of response.1,2 Recent systematic reviews and meta-analyses highlight the need for new, targeted therapies.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18 years.
- Clinical and/or histopathologic diagnosis of LPP.
- Presence of scalp pruritus.
- Average Peak Pruritus Numerical Rating Scale (PP-NRS) score ≥4 in the 7 days prior to Day 1.
- Ability and willingness to provide written informed consent and comply with study procedures.
You likely can't join if
- Other forms of alopecia that may interfere with study assessments.
- Any systemic disease associated with hair loss.
- Inflammatory or infectious scalp disease that may interfere with the study.
- Any other conditions associated with pruritus.
- Prior use of nemolizumab.
- Current treatment with systemic or topical JAK inhibitors or biologics (unless appropriate washout period completed; minimum 12 weeks).
See the full eligibility criteria
- Age ≥18 years.
- Clinical and/or histopathologic diagnosis of LPP.
- Presence of scalp pruritus.
- Average Peak Pruritus Numerical Rating Scale (PP-NRS) score ≥4 in the 7 days prior to Day 1.
- Ability and willingness to provide written informed consent and comply with study procedures.
- Willingness to undergo optional scalp biopsy for research purposes.
- Other forms of alopecia that may interfere with study assessments.
- Any systemic disease associated with hair loss.
- Inflammatory or infectious scalp disease that may interfere with the study.
- Any other conditions associated with pruritus.
- Prior use of nemolizumab.
- Current treatment with systemic or topical JAK inhibitors or biologics (unless appropriate washout period completed; minimum 12 weeks).
- Current treatment with DMARDs (unless appropriate washout period completed; minimum 12 weeks).
- Prior treatment failure of scarring alopecia with systemic or topical JAK inhibitors or
- biologics.
- Current treatment with topical or intralesional corticosteroids (unless appropriate washout period completed; minimum 4 weeks).
- Any other current treatments for hair loss (e.g., oral/topical minoxidil, PRP) unless stable for at least 6 months or 3 months washout completed.
- Allergy or hypersensitivity to nemolizumab or any excipients.
- Pregnancy or unwillingness to use highly effective contraception.
- Any medical condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results.
The study team makes the final eligibility decision.
Where it's taking place
- New City, New York, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New City, New York, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.